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Abstract
The genetic nature of sensorineural hearing loss (SNHL) has so far been studied for many ethnic groups in various parts of
the world. The single-nucleotide guanine deletion (35delG) of the GJB2 gene coding for connexin 26 was shown to be the
main genetic cause of autosomal recessive deafness among Europeans. Here we present the results of the first study of
GJB2 and three mitochondrial mutations among two groups of Belarusian inhabitants: native people with normal hearing
(757 persons) and 391 young patients with non-syndromic SNHL. We have found an extremely high carrier frequency of
35delG GJB2 mutation in Belarus 25.7%. This point deletion has also been detected in 53% of the patients with SNHL. The
312del14 GJB2 was the second most common mutation in the Belarus patient cohort. Mitochondrial A1555G mt-RNR1
substitution was found in two SNHL patients (0.55%) but none were found in the population cohort. No individuals carried
the A7445G mutation of mitochondrial mt-TS1. G7444A as well as T961G substitutions were detected in mitochondrial mt-
RNR1 at a rate of about 1% both in the patient and population cohorts. A possible reason for Belarusians having the highest
mutation carrier frequency in Europe 35delG is discussed.
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Introduction
The genetic mechanisms of hearing loss have been extensively
analyzed during the last two decades. Over 100 loci, both nuclear
and mitochondrial, are already implicated in the development of
this most common sensory disorder of humans [1]. The GJB gene
family (GJB2, GJB3 and GJB6) encoding gene gap junction
proteins – connexins – was found to be the main ‘‘storage place’’ of
mutations causing non-syndromic sensorineural hearing loss
(SNHL) [2–4]. More than 50% of cases of autosomal recessive
non-syndromic hearing loss in many world populations are
attributed to mutations in GJB2 gene encoding connexin 26
(OMIM: 121011) [5].
The most frequent GJB2 anomaly causing deafness in
Europeans and white Americans is deletion of one guanine within
the six-guanine string at the beginning of the second GJB2 exon
(positions 30–35), the so-called 35delG mutation (rs80338939)
[6,7]. Japanese people carry another recessive major GJB2
mutation, 235delC (rs80338943); its prevalence in Japan exceeds
73% [8]. V37I (rs72474224) is frequently found among Taiwan
natives [5] and 167delT (rs80338942) in Ashkenazi Jews [9].
Besides the point mutations and small deletions, several large
deletions were detected on the 13th chromosome within the region
where GJB2 and GJB6 genes are positioned close to each other.
These are the 309 kb (GJB6-D13S1830) and 232 kb deletions
(GJB6-D13S1854) located more than 100 kb upstream of the
transcriptional start sites of the GJB2 and GJB6 genes. Both
deletions are frequently detected in compound heterozygosity with
point GJB2 mutations [10,11].
The average carrier rate of 35delG GJB2 mutation in Europe is
about 2% [12]. In some Mediterranean countries (Italy (Sardinia)
Greece and Malta) it exceeds 3%. A moderately high rate (4.5%)
was reported for Estonia, one of the Baltic countries [3,5]. For one
of the Volga-middle Ural ethnic group, Mordvins, the 35delG
GJB2 carrier frequency is even higher (6.2%) [13]. All these values
are surprisingly high and point either to the ‘‘founder effect’’ or
selective advantage for heterozygotes, or both. Indeed, according
to a recent publication [14], the epidermal thickness is significantly
higher among European individuals heterozygous or homozygous
for 35delG compared to wild-type. These data stand in line with the
previously reported fact that Africans who carry the mutant GJB2
allele R134W (rs80338948) have a thicker epidermis than the wild-
type. In vitro studies have demonstrated that cells expressing the
R134W allele are significantly less susceptible to cellular invasion
of the enteric pathogen Shigella flexneri than wild-type cells [15,16].
These data support the hypothesis that skin phenotype might
counterbalance the evolutionary disadvantage caused by deafness
[14].
Besides the nuclear genes, a proper set of mitochondrial (mt)
genes is involved in the control of normal hearing [17,18,19].
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maternally inherited; they can be both in homo- and hetero-
plasmic states. Though definite mitochondrial point mutations and
large deletions usually lead to syndromic deafness [20,21], some
point mutations, notably in mt-RNR1 and mt-TS1 (tRNA
Ser) genes,
may cause SNHL [17]. A certain range of mutations in the mt-
RNR1 gene (A1555G, C1494T, T961G) was found to be associated
with aminoglycoside-induced deafness [22]. The incidence of these
mutations varies also among different populations; so far nothing
has been reported about Belarusian patients with SNHL.
As far as we know, the only data on the 35delG GJB2 carrier rate
among Belarusians (97 people with normal hearing) were
published in 2010 [13]. The carrier frequency was reported to
be more than 6%, the highest rate for European countries studied
so far. Here we present, firstly, results of an extensive analysis of
35delG/GJB2 carrier frequency among more than 750 modern
Belarusians from six ethno geographic regions of Belarus.
Secondly, we summarize the results of the analysis of GJB2 gene
structural changes along with the 309 kb deletion truncating the
neighboring GJB6 gene del(GJB6-D13S1830) in a large Belarus
patient cohort with SNHL (391 patients). Finally, both the Belarus
population and patient cohorts were screened for four mitochon-
drial mutations associated with deafness.
We provide here the genetic evidence that the carrier frequency
of the 35delG deafness mutation in the Belarus population is the
highest compared to other countries. The same GJB2 defect is the
main reason for SNHL in Belarus patients. Additionally our study
reveals that the second most common GJB2 mutation in the
Belarus patient cohort with SNHL is the 312del14 deletion.
Results and Discussion
Carrier rate of 35delG GJB2 mutation in Belarus
The number of persons genotyped in six regions of Belarus
(Figure 1) for estimation of the deafness major mutation carrier
rate is presented in table 1. The mutation was found in 43 out of
757 persons with normal hearing, i.e. 5.7% - a high rate of
incidence. We have found three regions of Belarus with an
extremely high carrier rate: the south-west of the country (west
Polessie) where it equals 10.2%, the northern part of Belarus
(Vitebsk region) 26.1% and south-east (east Polessie) 25.9%. The
northern part of Belarus is geographically proximal to Estonia,
where the carrier rate of 35delG was reported to be 4.5% [3].
Counter to this, in the western part of Belarus a carrier rate of 2%
was revealed that is comparable to the mean European frequency
for this mutation. The differences between 35delG carrier rate in
west Polessie and other regions of the country are therefore
significant.
According to the results obtained, the map of the European
distribution of 35delG carrier frequencies [23] should be corrected
since Belarusians are the population with the highest carrier rate
so far reported, not only for Europe, but for the other parts of the
world as well.
The high 35delG carrier rate in the Belarus population as a
whole, together with the uneven distribution of the mutation
carrier rate, seems surprising for this small country having no
geographically-isolated zones. Some previous studies have as-
sumed that the high frequency of the 35delG mutation reflects the
presence of a mutational hot spot [24,25], while others support the
theory of a common founder [26,27]. Greece is among the
countries with the highest carrier frequency of the mutation (3.5%)
and, according to the idea of a common founder, the 35delG
appeared about 10000 years ago in the territory of contemporary
Greece and expanded throughout Europe [28,29]. The alternative
model that a high frequency of the 35delG mutation reflects the
presence of a mutational hot spot seems a more probable
explanation of the results obtained here. To prove or reject any
of these hypotheses, single nucleotide polymorphisms adjacent to
GJB2 (haplotypes) should be analyzed and genotyping of the
native inhabitants from nearby Ukrainian and Polish Polessie and
the regions of Russia adjoining the northern part of Belarus should
be performed. A high 35delG carrier frequency (6.2%) was
reported recently for Mordvins, a small ethnic group that belongs
to the Finno-Ugric linguistic group and inhabits the Volga-middle
Ural region of Russia [13]. Taken together, Belarus as well as
Estonia and Mordovia are three European regions with a 35delG
carrier frequency almost three times higher than that generally
found in Europe and twice as high as that found in south-western
Europe and it would be fascinating to know whether these three
peaks are unrelated or have ‘‘common history’’ (Figure 2).
Data on the selective advantage of heterozygotes [14] should be
taken into account not only to explain the high rate of 35delG
mutation among Belarusians but also to interpret its uneven
distribution within the country depending on various ecological
conditions and the resulting unevenness in the distribution of skin
pathogens. Belarus Polessie (especially its western part, that was
found to have the highest carrier rate of 35delG mutation) is
situated in the south of Belarus where the humidity is extremely
high due to numerous swamps and dense woods, creating a
favorable environment for skin pathogens (Figure 1).
Analysis of the Belarus patient cohort with SNHL
35delG mutation. All 391 patients with SNHL were
screened for the 35delG GJB2 mutation. 178 patients (45.5%)
were homozygous for this genetic defect, 51 (13.1%) had only one
mutant allele and in 162 (41.4%) patients the major GJB2
mutation was not found (Table 2). Thus, as for other European
SNHL patient cohorts, the 35delG point deletion is the major
cause of prelingual SNHL among the Belarus patients studied.
The degree of SNHL varies among the studied Belarus patient
cohort from moderate to severe (five grades in total). Among
patients with moderate degree of hearing loss (HL) 72.2% lack the
mutation and only 16.7% have 35delG/35delG genotype whereas
among the patients with severe HL 36 out of 88 (40,9%) were
35delG homozygotes, with severe/profound HL 27 out of 45 (60%)
and with profound HL 105 out of 217 (48,4%) (Table 2, Figure 3).
Only 3 out of 178 homozygous 35delG patients have moderate HL
while 105 are totally deaf. Thus, based on the revealed phenotype-
genotype association we conclude that among the Belarus patient
cohort the 35delG/35delG genotype results mainly in severe and
profound hearing loss, which is similar to the other ethnic groups
previously studied [5,30].
Other mutations of the GJB2 gene and the del(GJB6-
D13S1830). SSCP analysis of the GJB2 coding exon was carried
out for all DNA samples heterozygous or lacking the 35delG
mutation. The samples with dissimilar mobility patterns were
sequenced. All the patients except 35delG homozygotes were
screened for the presence of GJB6 309 kb deletion: del(GJB6-
D13S1830). The results are summarized in table 3.
For 31 out of 51 patients bearing one 35delG allele, either
another mutation in GJB2 gene or the 309 kb deletion (GJB6-
D13S1830) was found; for the remaining 20 patients, only 35delG
was detected. According to our data, the second most common
GJB2 mutation causing SNHL in Belarus patient cohort is
312del14. We have detected 27 individuals bearing this mutation:
two patients without 35delG were homozygous for 312del14, 20
were 35delG/312del14 heterozygotes, and 5 patients lacking 35delG
had one deleted 312del14 allele. The overall 312del14 allele
35delG GJB2 Mutation in Belarusians
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nucleotide deletions or substitutions previously reported to cause
SNHL [3,5,31] were found in the Belarus patient cohort, all of
them with a frequency of less than 1% (0.77%–0.26%) (Table 3).
Notably, among 241 patients with SNHL that bear various GJB2
mutations, only four individuals were found with nucleotide
substitutions, while the vast majority bear deletions: single-
nucleotide (207 patients), deletion of 14 nucleotides (27 patients)
and 309 kb (3 patients).
Mitochondrial mutations in population and patient
cohorts. Two mitochondrial mutations, T961G and A1555G
(both are located in mt-RNR1), were screened in the sample of
300 normal hearing ethnic Belarusians. 595 individuals with
normal hearing were genotyped for the 7445/7444 (mt-TS1)
mutations. All individuals from the patient cohort were genotyped
for the four mtDNA mutations. The results are presented in
table 4.
No individuals from the population cohort bear the A1555G
mutation. Two patients with hearing loss possess this mitochon-
drial mutation (0.53%). Surprisingly, this rate is similar to that
found among 513 Greek children with hearing loss (0.4%) [32] but
is much less than the 3.6% found among SNHL patients of
neighboring Poland [33].
Two other mitochondrial mutations were found both in the
population and patient groups with rates 0.77–1.5%. There are
various opinions concerning T961G mutation: it is often consid-
ered as a non-pathogenic polymorphism, but there are reports
about its association with aminoglycoside-induced deafness and
Figure 1. Map of Belarus. Figures indicate the regions where the population samples have been collected; the Polessie region is shown dashed.
doi:10.1371/journal.pone.0036354.g001
Table 1. The rate of 35delG heterozygotes in the population cohort (native inhabitants from six regions of Belarus).
Belarus regions Detected 35delG heterozygotes/number of persons genotyped (%)
1 - center 5/126 (4.0)
2 - west 2/97 (2.0)
3 - east 5/127 (3.9)
4 - north 8/131 (6.1)
5 - south-west 16/157 (10.2)**
6 - south-east 7/119 (5.9)
Total 43/757 (5.7)
**The difference in rates between south-west and all the other regions is significant (P,0,02).
doi:10.1371/journal.pone.0036354.t001
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(1.5%), five of them are also 35delG homozygotes with a profound
(4 persons) or severe (1 person) degree of hearing loss and one of
these 6 patients has a non-mutant coding exon 2 of the GJB2 gene.
Thus, the cause of deafness in these five patients is probably the
35delG GJB2 pathogenic mutation, rather than the mitochondrial
T961G. In the population cohort, T961G substitution was found in
3 persons out of 300 analyzed individuals (1%), and all of them still
have normal hearing. Taking into consideration these results we
suppose that T961G is either a non-pathogenic polymorphism, or
possibly a pathogenic mutation with extremely low penetrance
among the Belarusian patients cohort studied.
The pathogenic role of G7444A is also questionable. It is
considered to be defining for mitochondrial haplogroup V [34],
but its role in aggravating the expression of the A1555G mutation
was also proposed [35]. G7444A incidence in the Belarusian
population and patient cohorts studied is about 1% (Table 4). A
high carrier rate of this mutation (1/62 or 1.6%) was found in
Poland and as a result this substitution was suggested to be a
nonpathogenic polymorphism in the Polish population [33]. In the
present study, three patients with this substitution do not bear any
mutation in either GJB2 or in the mt-RNR1 mitochondrial gene,
and the genetic origin of their profound hearing loss remains
uncertain.
In summary, the results from genotyping the large Belarus
population cohort for the 35delG mutation proves that the
frequency of this mutation (5.7%) is the highest among all
European countries studied. In one of the Belarus regions (west
Polessie) the mutation frequency exceeds 10%. We show that the
same single-nucleotide deletion, 35delG in GJB2, is also the main
genetic cause of SNHL in Belarus as it is detected in the homo- or
heterozygous state in 53% of the patients with moderate-to-
profound hearing loss. The higher the degree of hearing loss the
higher the proportion of 35delG homozygotes detected. Six other
mutations in the GJB2 gene were found: 312del14 in 7% of
patients and the rest in less than 1.5% of patients. The
mitochondrial A1555G mutation was revealed in less than 1% of
Figure 2. Geographic distribution of 35delG carrier rate. The spatial frequency map was obtained by plotting the incidence of the 35delG allele
in 4346 individuals representing 20 populations including 6 sub-populations from Belarus together with others taken from the literature [12,13]. The
frequency data were converted to the isofrequency map using Surfer software (version 7, Golden Software Inc., Golden, CO, USA). The right panel
shows how the color scale corresponds to 35delG allele frequency (%).
doi:10.1371/journal.pone.0036354.g002
Table 2. Genotype/phenotype correlations for the patients
with (D) and without (N) 35delG mutation.
SNHL degree
Patients
analyzed DD DN NN %DD/%NN
moderate 18 3 2 13 16.7/72.2**
moderate/severe 23 7 1 15 30.4/65.2
severe 88 36 11 41 40.9/46.6
severe/profound 45 27 7 11 60.0/24.4
profound 217 105 30 82 48.4/37.8
Total 391 178 51 162 45.5/41.4
**The difference of DD % with other patient groups is significant (P,0,02).
doi:10.1371/journal.pone.0036354.t002
Figure 3. Percentages of DD and NN 35delG genotypes among
Belarus SNHL patients with different degrees of hearing loss.
doi:10.1371/journal.pone.0036354.g003
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were found to carry G7444A substitution. We note that the rate of
G7444A substitution in the population cohort is about 1%,
evidence of its non-pathogenic state among Belarusians.
Materials and Methods
Ethics Statement
Both population and patient samples reported in the study were
collected after obtaining informed written consent; written
informed consent was obtained from the parents of the minors
who took part in this study. The study has been considered and
approved specifically by the Bioethics Committee of the Belarusian
State Medical University (Minsk, Belarus) and the Scientific Board
of the Institute of Genetics and Cytology of National Academy of
Sciences (Minsk, Belarus).
The research consisted of two parts as follows:
1. Analysis of the carrier rate of 35delG GJB2 mutation, as well as
mtDNA mutations among native Belarusian people with
normal hearing (referred to as the ‘‘population cohort’’ in the
main text)
2. Detection of 35delG GJB2, del(GJB6-D13S1830) deletions,
revealing other structural changes in the GJB2 gene along with
analysis of mtDNA mutations in the cohort of Belarus patients
with SNHL (referred to as the ‘‘patient cohort’’ in the main
text).
Subjects under study
Part 1- Population cohort study. To characterize the
Belarusian population, the country (9.5 million inhabitants) was
divided into six sampling regions according to the ethno
geographic approach; samples were collected in 2–4 small towns
from each region (Figure 1). Blood samples from 757 native
inhabitants of Belarus were collected after obtaining written
informed consent. Each person filled in the questionnaire
concerning his (her) ethnicity and place of birth, as well as
ethnicity and place of birth of his (her) parents and grandparents.
Only those volunteers who had normal hearing and lived in the
particular region of the country for three or more generations were
included in the study.
Part 2- Patient cohort study. 391 young patients, mostly
school- and preschool- children with sensorineural hearing loss
(non-relatives, aged 1–25) with or without family history of SNHL,
permanently living in Belarus, were taken into analysis after
obtaining a written consent to be involved into the study from their
parents or from themselves for adults. All hearing impaired
patients have passed otoscopic examination and different audio-
logical tests depending on their age: pure-tone audiometry,
impedance audiometry, distortion-product otoacoustic emission,
brainstem evoked response audiometry. Only those with bilateral
hearing loss were included in the study. Additionally, all patients
were assigned to groups according to the degree of SNHL (from
moderate to profound) based on the audiological tests. We note
that the patient cohort samples have been collected in the same six
regions of the country as the population cohort samples.
Table 3. The rates of GJB2 and del(GJB6- D13S1830) mutations in Belarus SNHL patient cohort.
GJB2 genotype Number of mutation carriers in patient cohort (%) Range of SNHL degree
*
35delG/35delG 178 (45.5) 3 mod, 7 mod/s, 35 s, 27 s/pr, 106 pr
35delG/312del14 20 (5.1) 2 mod, 1 mod/s, 3 s, 3 s/pr, 8 pr
N/312del14 5 (1.28) mod/s, s, s/pr, 2 pr
35delG/del(GJB6-D13S1830) 3( 0 . 7 7 ) p r
312del14/312del14 2( 0 . 5 1 ) p r
35delG/235delC 3( 0 . 7 7 ) s
167delT/235delC 2 (0.51) 1 s, 1 s/pr
35delG/I82M 2 (0.51) 1 mod, 1x
35delG/167delT 2 (0.51) 1 s, 1 s/pr
N/167delT 2 (0.51) 1 pr, 1 s/pr
N/V27I 1( 0 . 2 6 ) p r
35delG/V27I+E114G 1( 0 . 2 6 ) s
35delG/N 20 (5.1)
Total 241 (61.6)
*Degree of HL: mod – moderate; s – severe, pr – profound, x - no audiological data.
doi:10.1371/journal.pone.0036354.t003
Table 4. Rates of mitochondrial mutations in the Belarus population and patient cohorts with SNHL.
Mitochondrial mutation (%)
T961G MT-RNR1 A1555G MT-RNR1 G7444A MT-TS1 A7445G MT-TS1
Population Detected/studied 3/300 (1.0) 0/300 (0) 6/595 (1.01) 0/595 (0.0)
Patients Detected/studied 6/391 (1.5) 2/391 (0.51) 3/391 (0.77) 0/391 (0.0)
doi:10.1371/journal.pone.0036354.t004
35delG GJB2 Mutation in Belarusians
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was collected, whereas 50–100 mcl (1–2 drops) of peripheral blood
was collected for patients. DNA was isolated with proteinase K
and phenol-chloroform purification [36].
Strategy of genotyping
1) Population cohort study: the 35delG GJB2 mutation was
genotyped in 757 samples over six regions of Belarus. Smaller
sample sets (while still representing all the regions) were analyzed
for the presence of mitochondrial mutations. In particular, 300
samples were screened for mt-RNR1 mutations while mt-TS1
mutations were genotyped among 595 samples.
2) Patients cohort study
a) GJB genes: the 35delG GJB2 mutation was analyzed for all
patients with SNHL. Further, for the patients without the 35delG
mutation or heterozygous individuals, the SSCP technique was
used to detect the structural changes in the coding part of the
GJB2 gene. Direct sequencing of dissimilar patterns was used to
specify the nucleotide sequence change. All the patients except the
35delG homozygotes were screened for the 309 kb deletion:
del(GJB6-D13S1830) using a multiple PCR protocol [37].
b) Mitochondrial mutations A1555G, T961G, A7445G and
G7444A were detected after amplification with specific primers
and cleavage by endonucleases, all mitochondrial mutations found
were also confirmed by sequencing. See table 5 for all primers and
conditions of genotyping.
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mtDNA are given relative to the rCRS [40].
doi:10.1371/journal.pone.0036354.t005
35delG GJB2 Mutation in Belarusians
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36354c.167delT among the populations of Eurasia. J Hum Genet 55: 749–754. doi:
10.1038/jhg.2010.101.
14. Guastalla P, Guerci VI, Fabretto A, Faletra F, Grasso DL, et al. (2009) Detection
of epidermal thickening in GJB2 carriers with epidermal ultrasonography.
Radiology 251: 280–286. doi: 10.1148/radiol.2511080912.
15. Meyer CG, Amedofu GK, Brandner JM, Pohland D, Timmann C, et al. (2002)
Selection for deafness? Nat Med 8: 1332–1333. doi:10.1038/nm1202-1332.
16. Man YK, Trolove C, Tattersall D, Thomas AC, Papakonstantinopoulou A, et
al. (2007) A deafness-associated mutant human connexin 26 improves the
epithelial barrier in vitro. J Membr Biol 218: 29–37. doi: 10.1007/s00232-007-
9025-0.
17. Fischel-Ghodsian N (1999) Mitochondrial deafness mutations reviewed. Hum
Mutat 13: 261–270. doi: 10.1002/(SICI)1098–1004(1999)13:4.
18. Bitner-Glindzicz M (2002) Hereditary deafness and phenotyping in humans. Br
Med Bull 63: 73–94. doi: 10.1093/bmb/63.1.73.
19. Li R, Greinwald J, Yang L, Choo DI, Wenstrup RJ, et al. (2004) Molecular
analysis of the mitochondrial 12S rRNA and tRNASer(UCN) genes in paediatric
subjects with nonsyndromic hearing loss. J Med Genet 41: 615–620. doi:
10.1136/jmg.2004.020230.
20. Shanske AL, Shanske S, DiMauro S (2001) The other human genome. Arch
Pediatr Adolesc Med 155: 1210–1216.
21. Finsterer J (2004) Mitochondriopathies. Eur J Neurol 11: 163–186. doi:
10.1046/j.1351-5101.2003.00728.
22. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, Wendt KA, Nelson RA, et al.
(1997) Mitochondrial gene mutation is a significant predisposing factor in
aminoglycoside ototoxicity. Am J Otolaryngol 18: 173–178. doi: 10.1016/
S0196-0709(97)90078-8.
23. Lucotte G, Dieterlen F (2005) The 35delG mutation in the connexin 26 gene
(GJB2) associated with congenital deafness: European carrier frequencies and
evidence for its origin in ancient Greece. Genet Test 9: 20–26. doi:10.1089/
gte.2005.9.20.
24. Denoyelle F, Weil D, Maw MA, Wilcox SA, Lench NJ, et al. (1997) Prelingual
deafness: high prevalence of a30delG mutation in the connexin 26 gene. Hum
Mol Genet 6: 2173–2177.
25. Rabionet R, Gasparini P, Estivill X (2000) Molecular genetics of hearing
impairment due to mutations in gap junction genes encoding beta connexins.
Hum Mutat 16: 190–202. doi: 10.1002/1098–1004(200009)16:3.
26. Van Laer L, Coucke P, Mueller RF, Caethoven G (2001) A common founder for
the 35delG GJB2 gene mutation in connexin 26 hearing impairment. J Med
Genet 38: 515–518. doi: 10.136/jmg.38.8.515.
27. Rothrock CR, Murgia A, Sartorato EL (2003) Connexin 26 35delG does not
represent a mutational hotspot. Hum Genet 113: 18–23. doi 10.1007/s00439-
003-0944–2.
28. Antoniadi T, Rabionet R, Kroupis C, Aperis GA, Economides J, et al. (1999)
High prevalence in the Greek population of the 35delG mutation in the
connexin 26 gene causing prelingual deafness. Clin Genet 55(5): 381–382.
29. Kokotas H, Van Laer L, Grigoriadou M, Iliadou V, Economides J, et al. (2008)
Strong linkage disequilibrium for the frequent GJB2 35delG mutation in the
Greek population. Am J Med Genet A 146A: 2879–2884. doi: 10.1002/
ajmg.a.32546.
30. Cryns K, Orzan E, Murgia A, Huygen PL, Moreno F, et al. (2004) A genotype-
phenotype correlation for GJB2 (connexin 26) deafness. J Med Genet 41:
147–154. doi: 10.1136/jmg.2003.013896.
31. Palmada M, Schmalisch K, Bo ¨hmer C, Schug N, Pfister M, et al. (2006) Loss of
function mutations of the GJB2 gene detected in patients with DFNB1-
associated hearing impairment. Neurobiology of Disease 22: 112–118.
doi:10.1016/j.nbd.2005.10.005.
32. Kokotas H, Grigoriadou M, Korres GS, Ferekidou E (2011) Detection of
deafness-causing mutations in the Greek mitochondrial genome. Dis Markers
30: 283–289. doi: 10.3233/DMA–2011-0786.
33. Rydzanicz M, Wro ´bel M, Pollak A, Gawecki W, Brauze D, et al. (2010)
Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-
syndromic and aminoglycoside-induced hearing loss. Biochem Biophys Res
Commun 395: 116–121. doi:10.1016/j.bbrc.2010.03.149.
34. Van Oven M, Kayser M (2009) Updated comprehensive phylogenetic tree of
global human mitochondrial DNA variation. Hum Mutat 30: E386–394.
doi:10.1002/humu.20921.
35. Yang AF, Zhu Y, Lu JX, Yang L, Zhao JY, et al. (2008) [Mitochondrial DNA
G7444A mutation may influence the phenotypic manifestation of the deafness-
associated 12S rRNA A1555G mutation] [Article in Chinese]. Yi Chuan 30:
728–734.
36. Mathew CC (1984) The isolation of high molecular weight eucaryotic DNA. In:
Walker JMNJ, ed. Methods in Molecular Biology, Clifton: Human Press, vol. 2.
pp 31–34.
37. Toth T, Kupka S, Haack B, Fazakas F, Muszbek L, et al. (2007) Coincidence of
mutations in different connexin genes in Hungarian patients. Int J Mol Med 20:
315–321.
38. Wilcox SA, Saunders K, Osborn AH, Arnold A, Wunderlich J, et al. (2000)
High frequency hearing loss correlated with mutations in the GJB2 gene. Hum
Genet 106: 399–405. doi:10.1007/s004390000273.
39. Schon EA, Naini A, Shanske S (2002) Identification of mutations in mtDNA
from patients suffering mitochondrial diseases. In: Copeland WC, Clifton NJ,
eds. Mitochondrial DNA, Methods and protocols. [Methods Mol Biol,
vol. 197].Humana Press. pp 55–74.
40. Andrews R, Kubacka I, Chinnery P, Lightowlers R, Turnbull D, et al. (1999)
Reanalysis and revision of the Cambridge reference sequence for human
mitochondrial DNA. Nat Genet 2: 147. doi:10.1038/13779.
35delG GJB2 Mutation in Belarusians
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36354